Data showed that patients who had pathologic complete response in the neoadjuvant setting after treatment with a regimen containing Genetech's Perjeta experienced better progression-free and disease-free survival.
NEW YORK (GenomeWeb) – Roche this week announced plans to acquire Seragon Pharmaceuticals, aiming to bolster its own breast cancer pipeline and improve the standard of care for hormone receptor-positive breast cancer.
A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient
The US Food and Drug Administration has accepted a supplemental biologics license application for Perjeta (pertuzumab) as a neoadjuvant treatment for women with HER2-positive, early-stage breast cancer, Roche subsidiary Genentech announced this week.
Originally published June 3.
CHICAGO – Based on promising results from earlier studies, Pfizer is moving ahead with a Phase III trial to study the investigational agent palbociclib in estrogen receptor-positive, HER2-negative breast cancer patients.